USPTO Examiner CARR DEBORAH D - Art Unit 1692

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18808138Compositions and Methods for Treating Endocrine Diseases and DisordersAugust 2024October 2024Allow200NoNo
18396499COMPOSITION CONTAINING HIGHLY UNSATURATED FATTY ACID OR ALKYL ESTER THEREOF AND A METHOD FOR PRODUCING THE SAMEDecember 2023November 2024Allow1110NoNo
18390964NUTRITIONAL COMPOSITIONS FROM BREWERS' SPENT GRAIN AND METHODS FOR MAKING THE SAMEDecember 2023June 2024Allow510NoNo
18558067AMAROUCIAXANTHIN A ESTERS AND USES THEREOFOctober 2023June 2024Allow700NoNo
18241641SALTS OF TREPROSTINILSeptember 2023February 2025Abandon1710NoNo
18023293VINYL ACETATE PRODUCTION PROCESS AND DEVICEFebruary 2023December 2024Abandon2120NoNo
18150464IONIZABLE LIPID COMPOUNDSJanuary 2023July 2024Allow1911NoNo
17984331DOCOSAHEXAENOIC ACID-CONTAINING OIL AND METHOD FOR PRODUCING SAMENovember 2022September 2024Allow2220NoNo
17943512METHOD OF OIL EXTRACTIONSeptember 2022January 2025Abandon2820NoNo
17781394PROCESS FOR THE CONTINUOUS PREPARATION OF HEAVY ALKYL ACRYLATESJune 2022January 2025Allow3200NoNo
17723537METHOD AND SYSTEM FOR PRODUCING A PROTEIN AND FIBER FEED PRODUCT FROM A WHOLE STILLAGE BYPRODUCT PRODUCED IN A CORN DRY MILLING PROCESSApril 2022September 2024Allow2920NoNo
17584818METHOD FOR PURIFYING PHOSPHORUS-CONTAINING OLEFIN COMPOUND SALT AND METHOD FOR PRODUCING OLEFIN COMPOUND USING PURIFIED PRODUCT OBTAINED THEREBYJanuary 2022January 2025Allow3611NoNo
17545747PROCESS FOR PURIFYING LPC-DHA AND/OR LPC-EPA USING A CHROMATOGRAPHIC STATIONARY PHASE AND COMPOSITIONS THEREOFDecember 2021August 2024Allow3210NoNo
17614353METHOD OF EXTRACTING POLYHYDROXYLATED FATTY ALCOHOLS USING SUPERCRITICAL CO2November 2021May 2024Allow3010NoNo
17595736AN OIL EXTRACT COMPRISING DIHOMOLINOLENIC ACID, AND A PROCESS FOR PRODUCING THE OIL EXTRACTNovember 2021January 2025Abandon3810NoNo
17367548ORGANIC BASED EXTRACTION SYSTEMJuly 2021January 2025Abandon4211NoNo
17413584COMPOSITIONS AND METHODS FOR THE TREATMENT OF CUTANEOUS T CELL LYMPHOMA (CTCL)June 2021February 2025Abandon4410NoNo
17296742META-DIAMIDE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTSMay 2021October 2024Abandon4010NoNo
17324745COMPOSITIONS FOR FEEDING A PREGNANT ANIMALMay 2021September 2024Allow4010NoNo
17227786COMPOSITIONS AND METHODS FOR MODULATION OF EXTRACELLULAR VESICLE RELEASE AND TREATMENT OF NEUROLOGICAL DISORDERSApril 2021September 2024Allow4110NoNo
17282587COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LEBER'S HEREDITARY OPTIC NEUROPATHYApril 2021October 2024Abandon4301NoNo
17280092COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES AND/OR DISORDERS CAUSED BY EXPOSURE TO AIR POLLUTIONMarch 2021December 2024Abandon4510NoNo
17301076LEUCINE-ENRICHED KETOGENIC FORMULATIONSMarch 2021November 2024Allow4410NoNo
17275576METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A STATIN-TREATED SUBJECTMarch 2021November 2024Abandon4410NoNo
17250841A CATALYST AND ITS USE IN FATTY ACID ISOMERISATIONMarch 2021June 2024Allow3912NoNo
17273643CANNABIDIOL COMPOSITIONS HAVING MODIFIED CANNABINOID PROFILESMarch 2021June 2024Allow3910NoNo
17273034METHODS OF TREATING MYCOBACTERIAL INFECTIONS USING TETRACYCLINE COMPOUNDSMarch 2021June 2024Allow3910NoNo
17182794INTERMITTENT ENDURANCE CAPACITY IMPROVING AGENT OR BLOOD pH ELEVATING AGENTFebruary 2021October 2024Allow4420NoNo
17269751Applications of Known and Novel CannabinoidsFebruary 2021November 2024Allow4511NoNo
17056069COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENTNovember 2020November 2024Allow4820NoNo
17013919COMPOUNDS THAT MODULATE FATTY ACID RECEPTOR ACTIVITY AND PET FOOD PRODUCTS CONTAINING THE SAMESeptember 2020September 2024Allow4811NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner CARR, DEBORAH D - Prosecution Strategy Guide

Executive Summary

Examiner CARR, DEBORAH D works in Art Unit 1692 and has examined 19 patent applications in our dataset. With an allowance rate of 63.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner CARR, DEBORAH D's allowance rate of 63.2% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CARR, DEBORAH D receive 1.05 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CARR, DEBORAH D is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

Petition Practice

When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.